Boyu Liu Selected Research

prostaglandin-inositol cyclic phosphate

1/2022	Nrf2 Activation Mediates Antiallodynic Effect of Electroacupuncture on a Rat Model of Complex Regional Pain Syndrome Type-I through Reducing Local Oxidative Stress and Inflammation.
1/2022	Electroacupuncture Ameliorates Mechanical Allodynia of a Rat Model of CRPS-I via Suppressing NLRP3 Inflammasome Activation in Spinal Cord Dorsal Horn Neurons.
1/2021	Gene Expression Profiling of Contralateral Dorsal Root Ganglia Associated with Mirror-Image Pain in a Rat Model of Complex Regional Pain Syndrome Type-I.
9/2020	Electroacupuncture Alleviates Mechanical Allodynia in a Rat Model of Complex Regional Pain Syndrome Type-I via Suppressing Spinal CXCL12/CXCR4 Signaling.
5/2020	Expression profiling of spinal cord dorsal horn in a rat model of complex regional pain syndrome type-I uncovers potential mechanisms mediating pain and neuroinflammation responses.
1/2020	Electroacupuncture Alleviates Mechanical Allodynia of a Rat Model of CRPS-I and Modulates Gene Expression Profiles in Dorsal Root Ganglia.
1/2020	Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats.
1/2019	Transcriptome profiling of dorsal root ganglia in a rat model of complex regional pain syndrome type-I reveals potential mechanisms involved in pain.
1/2019	TRPV1 Channel Contributes to the Behavioral Hypersensitivity in a Rat Model of Complex Regional Pain Syndrome Type 1.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Boyu Liu Research Topics

Disease

16	Pain (Aches) 02/2022 - 01/2019
9	Hyperalgesia 01/2022 - 01/2019
6	Inflammation (Inflammations) 02/2022 - 01/2020
5	Chronic Pain 09/2022 - 01/2021
4	Neuralgia (Stump Neuralgia) 09/2022 - 01/2019
4	Hypersensitivity (Allergy) 01/2020 - 01/2019
3	Neuroinflammatory Diseases 01/2022 - 12/2020
3	Ischemia 01/2020 - 01/2019
2	Allergic Contact Dermatitis 02/2022 - 11/2019
2	Reflex Sympathetic Dystrophy (Reflex Sympathetic Dystrophy Syndrome) 01/2022 - 09/2020
2	Peripheral Nervous System Diseases (PNS Diseases) 02/2021 - 11/2019
2	Neoplasms (Cancer) 02/2021 - 01/2021
2	Gout 01/2020 - 01/2020
1	Virus Diseases (Viral Diseases) 09/2022
1	Contact Dermatitis (Eczema, Contact) 02/2022
1	COVID-19 01/2022
1	Postoperative Pain 01/2022
1	Jaundice (Icterus) 12/2021
1	Liver Neoplasms (Liver Cancer) 01/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021
1	Parkinson Disease (Parkinson's Disease) 12/2020
1	Nervous System Diseases (Neurological Disorders) 12/2020
1	Hemoptysis 05/2020
1	Atrial Fibrillation 05/2020
1	Pulmonary Vein Stenosis 05/2020
1	Hyperemia 01/2020
1	Edema (Dropsy) 01/2020
1	Arthritis (Polyarthritis) 01/2020
1	Hyperthermia 01/2019
1	Pneumonia (Pneumonitis) 01/2016
1	Necrosis 04/2013
1	Nematode Infections 09/2011

Drug/Important Bio-Agent (IBA)

9	prostaglandin-inositol cyclic phosphateIBA 01/2022 - 01/2019
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2019
3	InflammasomesIBA 01/2022 - 01/2020
3	Analgesics (Analgesic Drugs)IBA 01/2021 - 11/2019
3	CytokinesIBA 01/2019 - 04/2013
2	AllergensIBA 02/2022 - 11/2019
2	AntioxidantsIBA 01/2022 - 01/2020
2	LigandsIBA 01/2022 - 04/2013
2	Paclitaxel (Taxol)FDA LinkGeneric 02/2021 - 11/2019
2	immune RNA (I-RNA)IBA 01/2021 - 01/2019
2	salicylhydroxamic acid (SHAM)IBA 01/2021 - 09/2020
2	Capsaicin (Zostrix)FDA Link 01/2020 - 11/2019
2	Uric Acid (Urate)IBA 01/2020 - 01/2020
2	TRPA1 Cation ChannelIBA 01/2020 - 01/2019
2	Interleukin-10 (Interleukin 10)IBA 01/2016 - 09/2011
1	Proteins (Proteins, Gene)FDA Link 09/2022
1	Dopamine Receptors (Dopamine Receptor)IBA 09/2022
1	EnzymesIBA 01/2022
1	Nucleocapsid ProteinsIBA 01/2022
1	VaccinesIBA 01/2022
1	Cysteine (L-Cysteine)FDA Link 01/2022
1	Immunoglobulin A (IgA)IBA 01/2022
1	Secretory Immunoglobulin A (SIgA)IBA 01/2022
1	ImmunosorbentsIBA 01/2022
1	Scavenger Receptors (Scavenger Receptor)IBA 12/2021
1	Nerve Growth Factors (Neurotrophins)IBA 02/2021
1	Pharmaceutical PreparationsIBA 02/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Caspase 3 (Caspase-3)IBA 12/2020
1	Long Noncoding RNAIBA 12/2020
1	Taurine FDA Link 12/2020
1	Indomethacin (Indometacin)FDA LinkGeneric 01/2020
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020
1	AnkyrinsIBA 01/2020
1	EucalyptolIBA 01/2020
1	Therapeutic UsesIBA 01/2020
1	Interleukin-33IBA 01/2020
1	LipopolysaccharidesIBA 01/2019
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 01/2019
1	Endothelin-1 (Endothelin 1)IBA 01/2019
1	3- (4- t- butylphenyl)- N- (2,3- dihydrobenzo(b)(1,4)dioxin- 6- yl)acrylamideIBA 01/2019
1	Vasoconstrictor AgentsIBA 01/2019
1	CationsIBA 01/2019
1	Interleukin-18 (Interleukin 18)IBA 01/2016
1	Interleukin-8 (Interleukin 8)IBA 01/2016
1	cyclopropapyrroloindoleIBA 04/2013
1	Interleukin-6 (Interleukin 6)IBA 04/2013
1	Histocompatibility Antigens Class IIIBA 04/2013
1	Toll-Like Receptors (Toll-Like Receptor)IBA 04/2013

Therapy/Procedure

7	Electroacupuncture 09/2022 - 11/2019
3	Therapeutics 01/2022 - 11/2019
2	Drug Therapy (Chemotherapy) 02/2021 - 11/2019
1	Analgesia 09/2022
1	Fecal Microbiota Transplantation 09/2022
1	Physical Therapy Modalities (Physical Therapy Technique) 01/2022
1	Intraperitoneal Injections 12/2021
1	Radiofrequency Ablation 05/2020
1	Anesthesia 01/2020